In a study of patients with type 2 diabetes and chronic kidney disease, canagliflozin, an SGLT2 inhibitor, decreased the risk of end-stage renal disease by 32% compared with placebo.
Janssen announced the submission of a supplemental New Drug Application (sNDA) to the Food and Drug Administration (FDA) for Invokana (canagliflozin) to reduce the risk of end-stage renal disease and renal or cardiovascular (CV) death in adults with type 2 diabetes and chronic kidney disease.
Proliferative vs non-proliferative diabetic retinopathy in CKD patients is associated with a higher risk of CKD progression.
In a Finnish study, the cumulative risk for end-stage renal disease among patients with newly diagnosed with type 2 diabetes was less than 1% at 20 years.
Suppressing albuminuria should be an important target of therapy, according to investigators.
SGLT2i reduced the risks for progression of renal disease by 45% and heart failure hospitalization by 31% in patients with type 2 diabetes.
Treatment with bardoxolone methyl resulted in significant weight loss and showed no evidence of muscle wasting in patients with type 2 diabetes and stage IV chronic kidney disease.
Strict BP control, fenofibrate use may increase long-term risk for adverse kidney events in T2DM patients
Study results indicated that sitagliptin showed greater glycemic efficacy than dapagliflozin treatment.
Additional focus on lifestyle management, self-management education and support emphasized